CMBA
TXMD icon

C.M. Bidwell & Associates’s TherapeuticsMD TXMD Stock Holding History

C.M. Bidwell & Associates’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-195
Closed -$57K – 280
2015
Q3 		$57K Sell
195
-286
-59% -$102K 0.01% 210
2015
Q2 		$189K Buy
+481
New +$170K 0.04% 179

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

C.M. Bidwell & Associates's TXMD Position: Q4 2015 in Review

C.M. Bidwell & Associates sold out of TherapeuticsMD (TXMD) in Q4 2015, closing a stake of 195 shares — an estimated $57K sold.

C.M. Bidwell & Associates first reported a position in TXMD in Q2 2015 and held it in 2 quarters. The position peaked at $189K in Q2 2015. 123 funds tracked by Wall St. Rank hold TXMD as of Q4 2015.

  • C.M. Bidwell & Associates reported no remaining TherapeuticsMD position as of Q4 2015 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 195 TherapeuticsMD shares in Q4 2015, an estimated $57K.
  • C.M. Bidwell & Associates first reported a position in TherapeuticsMD in Q2 2015 and held it in 2 quarters.
  • C.M. Bidwell & Associates's TherapeuticsMD position peaked at $189K in Q2 2015.
  • 123 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2015.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2015, filed 12 Feb 2016.